GLP-1 drugs and endometriosis pain: what the data says

What did @byjadewalker actually say?

This naturopath, who has endometriosis herself, is crowd-sourcing patient experiences with GLP-1 receptor agonists and pain relief. She reports hearing about "significant reductions in inflammation and pain" from people with conditions like endometriosis, and says her own views on these medications have shifted considerably. She stops short of making a direct medical recommendation, framing this as curiosity and community-building rather than clinical advice. Credit where it's due: that's a more honest framing than most GLP-1 content on TikTok.

She also floats the idea that GLP-1 agonists could be "the new longevity medication" and says she's personally tempted to try one. That's a meaningful disclosure, but it also matters who's saying it. A naturopath's clinical experience does not substitute for controlled trial data, and the comments section of a TikTok video is not a valid data collection method for drug effects.

Does the science back this up?

The anti-inflammatory angle is real, but it's early-stage research that does not yet extend clearly to endometriosis specifically. GLP-1 receptors are found on immune cells, and preclinical data shows GLP-1 agonists can reduce inflammatory cytokine expression. But "reduces systemic inflammation in some contexts" is not the same as "treats endometriosis pain."

A 2023 paper by Becker and colleagues in Nature Metabolism showed semaglutide reduced neuroinflammation in mouse models, which is promising but not human trial data. A 2024 review in Obesity Reviews (Pradhan et al.) confirmed GLP-1 agonists reduce CRP and IL-6 in people with obesity, independent of weight loss. Endometriosis is an estrogen-driven, inflammatory condition, so the mechanistic logic isn't crazy. But as of mid-2025, there are no published randomized controlled trials examining GLP-1 agonists specifically for endometriosis pain. What exists is anecdote, mechanism plausibility, and a lot of social media signal.

What did they get wrong (or right)?

She got the tone mostly right. Calling this an "emerging space" is accurate. Acknowledging that all medications carry risk profiles is accurate. Saying her mind has changed based on patient outcomes is honest, if methodologically weak.

Where she veers into shakier territory is the suggestion that GLP-1 agonists could be "the new longevity medication." That framing outruns the evidence significantly. Longevity claims require long-term mortality data, and we don't have that for GLP-1 agonists yet. The cardiovascular outcome data from SUSTAIN-6 and SELECT trials is genuinely impressive, but cardiovascular risk reduction in high-risk populations is not the same as a longevity drug for the general public.

She also does not mention that semaglutide and tirzepatide are not approved for endometriosis, meaning anyone using them for that purpose is doing so off-label, which carries its own implications for monitoring, dosing, and insurance coverage. That omission matters when your audience is patients looking for answers.

What should you actually know?

If you have endometriosis and you're wondering whether a GLP-1 agonist might help with your pain, that is a legitimate question worth raising with a physician. The anti-inflammatory mechanisms are biologically plausible, and some patients do report pain reduction. But anecdote-driven decisions about prescription medications are risky, particularly when the drug in question requires medical supervision, has a real side-effect profile including nausea, gastroparesis risk, and potential thyroid concerns, and is not currently indicated for your condition.

What you should actually do is talk to a doctor who knows your full history, not reverse-engineer a prescription from a TikTok comments section. The correct path for accessing GLP-1 medications is through licensed telehealth or in-person providers who can assess appropriateness, monitor labs, and adjust treatment. The science on inflammation is interesting enough to follow. It is not yet strong enough to self-prescribe around.